Latest Financial Performance News

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

The Star Entertainment Group reported a 9% revenue decline to $271 million in Q3 FY25 alongside a $21 million EBITDA loss, driven by seasonal factors and operational challenges. The company is advancing strategic investments and joint venture exits amid ongoing liquidity pressures and regulatory hurdles.

Codeifai Limited reports a robust 141% increase in Q1 2025 cash receipts, driven by its revamped Digital First Engagement First strategy and the expanding ConnectQR SaaS platform. Despite rising costs, the company maintains strong margins and is strategically reviewing its Material Science division.

Vintage Energy reported a dip in quarterly sales and production but achieved cost savings and secured a key permit renewal, positioning itself for a production uplift program despite recent flooding delays.

DXN Limited reported a modest 2% revenue increase to $2.5 million in Q3 FY25, launched its Data Centre as a Service division with a $3.6 million initial contract, and progressed a key acquisition valued at $10 million, positioning itself for growth despite some project delays.

FirstWave’s Q3 FY25 update reveals steady contract renewals alongside tighter cash reserves, as the cybersecurity firm advances strategic partnerships and operational efficiencies.

MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.

Linius Technologies embarks on a strategic transformation under CEO Ben Taverner, focusing on operational restructuring, AI-enhanced SaaS products, and market expansion beyond sports to achieve breakeven by June 2026.

Atomos Limited reported a $2.3 million operating cash outflow in Q3 FY25 amid seasonal softness and tariff challenges, while announcing a leadership change and a bold expansion into new product categories beyond its core monitor-recorder business.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Omni Bridgeway reports robust investment performance for FY25, highlighted by record proceeds and a landmark Fund 9 transaction that strengthens its balance sheet and strategic position.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.